News / Taiwan / cnyes
Bora Pharmaceuticals Reports Strong August Revenue Growth of 59.22% YoY
Health Technology · Pharmaceuticals: Major · cnyes · 2026-09-07
6472
Bora Pharmaceuticals (6472.TW) announced August revenue of NT$2.185 billion, marking a significant 59.22% year-over-year increase and 14.89% monthly growth.
What Happened
Revenue Performance: Bora Pharmaceuticals (6472.TW) reported August 2026 revenue of NT$2.185 billion, representing a robust year-over-year increase of 59.22% and a monthly growth of 14.89%. Cumulative revenue for the first eight months of the year reached NT$13.979 billion, reflecting a year-to-date growth rate of 6.09%.
Market Performance: The company's stock price recently closed at NT$416. While the stock declined by 4.37% over the past five trading days, it outperformed the broader biotechnology sector index, which fell by 9.3% during the same period, indicating relative resilience.
Business Scope: Operating within the biotechnology and healthcare sector, Bora specializes in pharmaceutical manufacturing, as well as the agency and distribution of Western medicines and health supplements. The company leverages a diversified business model to maintain its market position.
Investment Note: The provided financial data is for informational purposes only and does not constitute investment advice. Investors are encouraged to conduct their own research and consider market conditions before making financial decisions.